Auro Laboratories Limited

AUROLAB6

INE292C01011

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 08:00:41 18/05/2024 BST			5-day change	1st Jan Change
232.1 ^INR	0.00%		-8.57%	+79.51%

03-30	Auro Laboratories Limited Announces Cessation of Kailash Chand Bubna as Independent Director	CI
02-06	Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023

September 25, 2023 at 11:50 am

Auro Laboratories Limited announced that Mr. Amit Mahipat Shah has resigned as Chief Financial Officer (KMP) of the Company with effect from October 1, 2023. The Company is in the process of appointing a new Chief Financial Officer and the same will be communicated to the Stock Exchanges in due course.

Latest news about Auro Laboratories Limited

Auro Laboratories Limited Announces Cessation of Kailash Chand Bubna as Independent Director	03-30	CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-06	CI
Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer	12-22	CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023	25/09/23	CI
Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director	23/09/23	CI
Auro Laboratories Plans to Spend INR400 Million to Expand Capacity of Metformin HCL Factory	24/08/23	MT
Auro Laboratories Limited Announces Intimation Regarding Capacity Expansion	23/08/23	CI
Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director	23/08/23	CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	31/07/23	CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	16/05/23	CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Auro Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	02/08/22	CI
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Auro Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Auro Laboratories Limited Announces Management Changes	30/05/22	CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	28/01/22	CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	11/11/21	CI
Auro Laboratories Limited Approves the Appointment of Kiran Kulkarni as the Whole-Time Director of the company	06/08/21	CI
Auro Laboratories' : Net Profit Surges in Fiscal Q4	22/06/21	MT
Auro Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21/06/21	CI
Auro Laboratories Limited Appoints Mrs. Kavita Sharma as Independent Director	11/02/21	CI
Auro Laboratories Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	11/02/21	CI
Auro Laboratories Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	05/11/20	CI

Chart Auro Laboratories Limited

Duration

Period

More charts

Company Profile

Auro Laboratories Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs), intermediates and generic formulations. The Company operates through the Pharmaceuticals segment. It offers APIs under categories, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids anti-inflammatory and others. Its products under intermediates include Glibenclamde Sulphonamide, Cis-bramo benzoate, Cls-Tosylate, 2-Ethoxy Benzoic Acid, 3,4,5, Trimethoxy Benzoic Acid and 5-Bromo Phthalide. It also undertakes toll/custom manufacturing for APIs and Intermediates on contract basis. The Company has a presence in international markets with bulk of its production being exported to Southeast Asia, Middle East and several European Countries. Some of the countries it exports to are Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain and United Kingdom.

Sector

Pharmaceuticals

Calendar

27/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AURO LABORATORIES LIMITED	+79.51%	16.97M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B